CO6280493A2 - Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
CO6280493A2
CO6280493A2 CO10049261A CO10049261A CO6280493A2 CO 6280493 A2 CO6280493 A2 CO 6280493A2 CO 10049261 A CO10049261 A CO 10049261A CO 10049261 A CO10049261 A CO 10049261A CO 6280493 A2 CO6280493 A2 CO 6280493A2
Authority
CO
Colombia
Prior art keywords
benzimidazol
approximately
carboxamida
pirrolidin
methyl
Prior art date
Application number
CO10049261A
Other languages
English (en)
Inventor
Lawrence Kolaczkowski
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6280493(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of CO6280493A2 publication Critical patent/CO6280493A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Forma cristalina 1 de 2-((R)-2-metilpirrolidin-2-il)-1H-benzimidazol-4-carboxamida la cual, cuando se mide a aproximadamente -100°C en el sistema cristalino tetragonal and grupo espacial P43212 con radiación a 0,7107 Å, se caracteriza por los valores de parámetros reticulares a, b y c de 8,218 Å ± 0,002Å, 8,218 ű 0,002 Å and 36,06 Å ± 0,01 Å, respectivamente, y valores a, ß y ? de 90°.2.- Forma cristalina 1 de 2-((R)-2-metilpirrolidin-2-il)-1H-benzimidazol-4-carboxamida la cual, cuando se mide a aproximadamente 25°C con radiación a 1,54178 Å, se caracteriza por un patrón de difracción en polvo que tiene valores 2? de aproximadamente 9,9°, 11,0° y 11,8°, respectivamente, y uno o más picos adicionales que tienen valores 2? de aproximadamente 14,6°, 15,2°, 18,2°, 19,6°, 20,3°, 21,3°, 22,5°, 22,8°, 24,7°, 28,5° and 29,1°, respectivamente.
CO10049261A 2007-10-12 2010-04-27 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida CO6280493A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
CO6280493A2 true CO6280493A2 (es) 2011-05-20

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10049261A CO6280493A2 (es) 2007-10-12 2010-04-27 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (27)

Country Link
US (4) US8372987B2 (es)
EP (2) EP2722046B1 (es)
JP (4) JP2011500589A (es)
KR (2) KR20160039312A (es)
CN (2) CN101821270A (es)
AU (1) AU2008310781B2 (es)
BR (1) BRPI0816221A8 (es)
CA (2) CA3006332A1 (es)
CO (1) CO6280493A2 (es)
CR (1) CR11368A (es)
DK (1) DK2722046T3 (es)
DO (1) DOP2010000099A (es)
EC (1) ECSP10010150A (es)
ES (1) ES2620299T3 (es)
GT (1) GT201000080A (es)
MX (1) MX350019B (es)
MY (1) MY156691A (es)
NZ (1) NZ583209A (es)
PA (1) PA8798401A1 (es)
PL (1) PL2722046T3 (es)
PT (1) PT2722046T (es)
RU (2) RU2476434C2 (es)
SG (1) SG185297A1 (es)
TW (1) TWI422588B (es)
UA (2) UA101961C2 (es)
WO (1) WO2009049111A1 (es)
ZA (1) ZA201002090B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3006332A1 (en) 2007-10-12 2009-04-16 Abbvie Ireland Unlimited Company 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
EP2217603B1 (en) 2007-10-12 2015-11-18 AbbVie Bahamas Ltd. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
WO2017152846A1 (zh) * 2016-03-09 2017-09-14 苏州晶云药物科技有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CA3006332A1 (en) 2007-10-12 2009-04-16 Abbvie Ireland Unlimited Company 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
EP2217603B1 (en) * 2007-10-12 2015-11-18 AbbVie Bahamas Ltd. 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2

Also Published As

Publication number Publication date
JP2017071618A (ja) 2017-04-13
CN101821270A (zh) 2010-09-01
PA8798401A1 (es) 2009-05-15
MX2010003772A (es) 2010-04-21
EP2722046A1 (en) 2014-04-23
US9580410B2 (en) 2017-02-28
RU2012147692A (ru) 2014-05-20
CA3006332A1 (en) 2009-04-16
JP2019001811A (ja) 2019-01-10
CN105367554A (zh) 2016-03-02
US20090099245A1 (en) 2009-04-16
NZ583209A (en) 2012-06-29
JP2014237659A (ja) 2014-12-18
US8835647B2 (en) 2014-09-16
CR11368A (es) 2010-10-25
TW200932747A (en) 2009-08-01
US20140024838A1 (en) 2014-01-23
ZA201002090B (en) 2011-11-30
SG185297A1 (en) 2012-11-29
RU2010116397A (ru) 2011-11-20
US20130123317A1 (en) 2013-05-16
EP2722046B1 (en) 2016-12-21
MX350019B (es) 2016-12-09
ES2620299T3 (es) 2017-06-28
JP2011500589A (ja) 2011-01-06
ECSP10010150A (es) 2010-06-29
DK2722046T3 (en) 2017-03-20
CA2696424A1 (en) 2009-04-16
US20150148392A1 (en) 2015-05-28
RU2476434C2 (ru) 2013-02-27
US8372987B2 (en) 2013-02-12
PL2722046T3 (pl) 2017-06-30
BRPI0816221A8 (pt) 2015-09-22
KR20160039312A (ko) 2016-04-08
DOP2010000099A (es) 2017-04-30
UA113277C2 (xx) 2017-01-10
MY156691A (en) 2016-03-15
AU2008310781A1 (en) 2009-04-16
CA2696424C (en) 2018-07-10
WO2009049111A1 (en) 2009-04-16
EP2212327A1 (en) 2010-08-04
GT201000080A (es) 2012-04-03
PT2722046T (pt) 2017-03-15
KR20100090769A (ko) 2010-08-17
TWI422588B (zh) 2014-01-11
UA101961C2 (en) 2013-05-27
BRPI0816221A2 (pt) 2015-06-16
AU2008310781B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CO6280493A2 (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
ATE478809T1 (de) Verschlusssystem mit verbessertem deckelverschluss
BRPI0819857A2 (pt) Fecho com saliências inibidoras de rotação aperfeiçoadas.
DK1939107T3 (da) Genlukkelig lukning med pakkeintegritetsfunktion
ATE512077T1 (de) Manipulationssicherer verschluss
ATE501056T1 (de) Fälschungssicherer verschluss
BRPI0907746A2 (pt) Documento de segurança compreendendo uma característica de segurança tendo uma camada com partículas
FI20075295A (fi) Ovenlukko
DE602007000505D1 (de) Pulverzusammensetzungen mit Beta-Hydroxyalkylamiden von der Ringöffnung saurer Verbindungen
RS54716B1 (en) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
AR059913A1 (es) Cristales modificados de (5s)-5-[4-(5cloropiridin-2-iloxi)piperidina-1-sulfonilmetil]-5-metilimidazolidina-2,4 diona. procesos de obtencion y composiciones farmaceuticas.
CL2014001021A1 (es) Compuestos heterociclicos sustituidos con 1,3 diarilo; composicion que lo comprende; y su uso para controlar una plaga de invertebrados.
FI20075296A0 (fi) Ovenlukko
BRPI0820227A2 (pt) Fechadura magnética
DE502006005317D1 (de) Webschaft mit Selbstspannverschluss
DE602006018941D1 (de) VERTEILERDICHTUNG MIT STÖßELSTANGENFÜHRUNG
ES1072762Y (es) Cerradura con llave
ITTO20060115A1 (it) Serratura di sicurezza
FI9594U1 (fi) Levyhaitta- tai elektroninen lukkosylinteri
FR2929978B1 (fr) Serrure a cremone reversible
FR2946105B3 (fr) Fermeture antivol.
ITNA20050037A1 (it) Lucchetto di sicurezza
IT1393220B1 (it) Serramento di chiusura
ITGO20080006A1 (it) Serratura utilizzabile con chiavi di diverso tipo
ES1066309Y (es) Panel para el cercado de obras

Legal Events

Date Code Title Description
FC Application refused